From Code to Cure: AI’s Role in the Drug Development and Clinical Trials, 30 June | Event in Rehovot | AllEvents

From Code to Cure: AI’s Role in the Drug Development and Clinical Trials

Recipharm

Highlights

Mon, 30 Jun, 2025 at 05:30 pm

2.5 hours

Dublin Pub

Free Tickets Available

Advertisement

Date & Location

Mon, 30 Jun, 2025 at 05:30 pm to 08:00 pm (GMT+03:00)

Dublin Pub

1 HaMada Street, Rehovot, Israel

Save location for easier access

Only get lost while having fun, not on the road!

About the event

From Code to Cure: AI’s Role in the Drug Development and Clinical Trials
This meetup hosted by Recipharm, spotlighting how AI is reshaping the pharmaceutical and healthcare industries.

About this Event


From Code to Cure: AI’s Role in Drug Development and Clinical Trials

Join us for an exclusive evening exploring how artificial intelligence is transforming the pharmaceutical landscape, from early-stage drug discovery to real-world clinical trials.

This event, hosted by Recipharm, brings together leading voices from biotech, healthcare, and academia to discuss the real-world impact of AI in pharma.

Our speakers includes:

Yogev Debbi (ManaBio, CEO): "AI-Driven design of Lipid Nanoparticles for RNA Delivery"

Prof. Boaz Lerner (Ben-Gurion University / Panacea, founder): "Developing AI models to optimize clinical trial design"

Marina Naomi Smolyanov (Clalit Health Services, Innovation Operation Manager): "AI in Action: Driving Scalable Innovation in Public Healthcare Systems"

Whether you're in biotech, pharma, healthcare, or data science, this is your chance to gain insights, ask questions, and network with professionals shaping the future of medicine.




Yogev Debbi


Title: CEO & Co-Founder, ManaBio
Yogev Debbi is the Co-founder and CEO of Mana.bio, an AI-driven drug delivery company leveraging machine learning and high-throughput screening to develop tissue-specific lipid nanoparticle (LNP) delivery solutions. Under his leadership, Mana.bio has pioneered a data-driven approach to unlocking extrahepatic delivery of nucleic acid therapeutics.
Prior to founding Mana.bio, Yogev co-founded Genome Compiler, a leading gene editing software platform that was acquired by Twist Bioscience (Nasdaq: TWST), a global leader in synthetic biology. Following the acquisition, he served as General Manager of Twist’s Israel R&D center, playing a key role in the company's IPO.
Yogev later held a senior leadership position at monday.com (Nasdaq: MNDY), contributing to its successful IPO and growth as a global enterprise software leader.

In his talk, "AI-Driven design of Lipid Nanoparticles for RNA Delivery" Yogev will discuss how Mana.bio integrates machine learning with high-throughput screening to develop tissue-specific LNPs that enable targeted delivery of RNA therapeutics beyond the liver (extrahepatic delivery). He will highlight the company’s innovative, data-driven approach to overcoming one of the most significant challenges in nucleic acid drug delivery.



Prof. Boaz Lerner

Title: Professor, Ben-Gurion University | Founder, Panacea
Prof. Boaz Lerner is a data scientist and professor at Ben-Gurion University, known for his pioneering work in machine learning applications in biomedicine. He is also the founder of Panacea, a company leveraging AI to revolutionizes clinical trial design with its data-driven. His research spans predictive modeling, bioinformatics, and decision support systems in healthcare.
In his talk about "Developing AI models to optimize clinical trial design and execution"
Boaz will focus on how AI is reshaping the drug development pipeline from target identification to clinical trials.



Marina Naomi Smolyanov

Title: Innovation Leader, Clalit Health Services
Marina Naomi Smolyanov is a leading figure in healthcare innovation at Clalit, the largest and most advanced health organization in Israel. With a background in digital health strategy and cross-sector collaboration, she focuses on integrating AI and emerging technologies into clinical workflows. Her work bridges the gap between healthcare providers, startups, and research institutions to drive scalable, patient-centered innovation.

In her talk about "AI in Action: Driving Scalable Innovation in Public Healthcare Systems"
Marina will focus on how AI is being implemented in large-scale healthcare environments, lessons learned from Clalit’s innovation journey, and the future of digital transformation in public health.


Also check out other Health & Wellness events in Rehovot, Meetups in Rehovot.

interested
Stay in the loop for updates and never miss a thing. Are you interested?
Yes
No

Ticket Info

Tickets for From Code to Cure: AI’s Role in the Drug Development and Clinical Trials can be booked here.

Ticket type Ticket price
General Admission Free
Advertisement

Nearby Hotels

Dublin Pub, 1 HaMada Street, Rehovot, Israel

Just a heads up!

We have gathered all the information for you in one convenient spot, but please keep in mind that these are subject to change. We do our best to keep everything updated, but something might be out of sync. For the latest updates, always check the official event details by clicking the "Find Tickets" button.

Register for Free

Host Details

Recipharm

Recipharm

Are you the host? Claim Event

Advertisement
From Code to Cure: AI’s Role in the Drug Development and Clinical Trials, 30 June | Event in Rehovot | AllEvents
From Code to Cure: AI’s Role in the Drug Development and Clinical Trials
Mon, 30 Jun, 2025 at 05:30 pm
Free